Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 2nd International Workshop on High-risk Multiple Myeloma (iwHRMM 2025) took place in Charleston, SC, on 22-24 October, 2025. This meeting brought together the world’s leading clinical researchers to discuss the latest advances in high-risk multiple myeloma.
The iwHRMM 2025 Workshop was supported by GSK (Platinum), Johnson & Johnson (Platinum), Legend Biotech (Silver), Regeneron (Silver), Sanofi (Silver), K36 Therapeutics (Bronze), Kite Pharma / Arcellx (Bronze) and SkylineDx (Bronze). Supporters have no influence over the production of content.
iwHRMM 2025
The 2nd International Workshop on High-risk Multiple Myeloma
22–24 October 2025 | Charleston, SC
The 2nd International Workshop on High-risk Multiple Myeloma (iwHRMM 2025) took place in Charleston, SC, on 22-24 October, 2025. This meeting brought together the world’s leading clinical researchers to discuss the latest advances in high-risk multiple myeloma.
The iwHRMM 2025 Workshop was supported by GSK (Platinum), Johnson & Johnson (Platinum), Legend Biotech (Silver), Regeneron (Silver), Sanofi (Silver), K36 Therapeutics (Bronze), Kite Pharma / Arcellx (Bronze) and SkylineDx (Bronze). Supporters have no influence over the production of content.
Roundtable discussions
View all
Expert interviews
View all
High-risk multiple myeloma (part I)
A T-cell signature identifying HR patients in MM
Wee Joo Chng National University Hospital Singapore, Kent Ridge, Singapore
The detection of PR cells at single-cell level identifies high-risk disease in myeloma
Paola Neri University of Calgary, Calgary, Canada
Genomic profile of high-risk MM without t(4;14) and del17p
Mehmet Samur Dana-Farber Cancer Institute, Boston, MA, United States
High-risk multiple myeloma (part II)
Metabolic vulnerabilities in t(14;16) MM
Wee Joo Chng National University Hospital Singapore, Kent Ridge, Singapore
Triggering immunogenic cell death to overcome high-risk MM
Kenneth Anderson Dana-Farber Cancer Institute, Boston, MA, United States
Coming Soon
High-risk multiple myeloma in the immunotherapy era
Francesco Maura Memorial Sloan Kettering Cancer Center, New York, NY, United States
Definition and outcomes of high-risk multiple myeloma in recent clinical trials
Martin Kaiser The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
Coming Soon
Malignant plasma cell biology
Transcriptional drivers of aggressive clinical behaviour
Gareth Morgan NYU Langone Health, New York City, NY, United States
Elevated circulating tumor cell numbers associate with a highly proliferative and genomically complex phenotype in NDMM
Juan José Garcés Memorial Sloan Kettering Cancer Center, New York, NY, United States
Extramedullary disease biology
High-risk features of bone marrow-independent disease
Niels Wienhold Heidelberg University, Heidelberg, Germany
Coming Soon
Extramedullary disease versus paraskeletal disease – is there a biological difference?
Saurabh Zanwar Mayo Clinic, Rochester, MN, United States
Overcoming spatial sampling bias by liquid biopsy
Johannes Waldschmidt University of Würzburg, Würzburg, Germany
MMSET disease subset
Prognostic impact of t(4;14), alone and in combination with other genomic risk factors
Kylee Maclachlan Memorial Sloan Kettering Cancer Center, New York, NY, United States
Pharmacologic and phenotypic targeting of t(4;14) MM
Benjamin Barwick Winship Cancer Institute of Emory University, Atlanta, GA, United States
Functional genomics studies to define therapeutic targets for high-risk MM
Constantine Mitsiades Dana-Farber Cancer Institute, Boston, MA, United States
Coming Soon
Immuno- and targeted therapies
Targeting GPRC5D: outcomes in high-risk subgroups
Ajai Chari University of California San Francisco (UCSF), San Francisco, CA, United States
Role of ADCs in the management of high-risk myeloma
Nisha Joseph Emory University School of Medicine, Atlanta, GA, United States
Coming Soon
Multiple antigen targeting to overcome resistance to T-cell redirecting therapy for high risk myeloma
Peter Voorhees Levine Cancer Institute, Atrium Health, Charlotte, NC, United States
Coming Soon
CAR therapies
Defining high-risk multiple myeloma in the era of CAR T-cell therapy
Sham Mailankody Memorial Sloan Kettering Cancer Centre, New York City, NY, United States
Coming Soon
Optimizing CAR T-cell therapy for high-risk multiple myeloma
Doris Hansen Moffitt Cancer Center, Tampa, FL, United States
Coming Soon
Allo and in vivo: off-the-shelf cell therapies for multiple myeloma
Karlo Perica Memorial Sloan Kettering Cancer Center, New York, NY, United States
Coming Soon
Resistance to immuno- and targeted therapies
Novel myeloid-derived resistance mechanisms for CAR-T/TCE therapies
Samir Parekh Icahn School of Medicine at Mount Sinai, New York, NY, United States
Coming Soon
Resistance to bispecific antibodies: focus on genomics
Holly Lee University of Calgary's Cumming School of Medicine, Calgary, Canada
Resistance to bispecific antibodies: focus on high-risk immune profile
Ross Firestone Memorial Sloan Kettering Cancer Center, Montvlae, NJ, United States
Coming Soon
MAF/MAFB disease
Modeling high-risk MM genetic and immune features in mice
José Ángel Martínez-Climent University of Navarra, Pamplona, Spain
Novel biomarkers for guiding the use of immunotherapies
Frank Zhan University of Arkansas for Medical Sciences, Little Rock, AR, United States
Coming Soon
Single-arm studies
Bispecific antibody-based approaches to HRMM
Marc Raab Heidelberg Myeloma Center, Heidelberg, Germany
Innovative trial designs for high-risk myeloma
Sham Mailankody Memorial Sloan Kettering Cancer Centre, New York City, NY, United States
Coming Soon
Leveraging consistent profiling for single-arm trials with external comparators
Martin Kaiser The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
Coming Soon
Randomized studies
Importance of translational studies in clinical trials of HRMM
Maximilian Merz Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Coming Soon
Microenvironmental contributions to high-risk disease
Robert Orlowski The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Role of MRD in randomized trials
Francesca Gay University of Turin, Turin, Italy
Coming Soon
Optimizing the timing of immunotherapy in randomized trials for high-risk myeloma
Binod Dhakal Medical College of Wisconsin, Milwaukee, WI, United States
